Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,577 | 695 | 99.6% |
| Education | $69.67 | 12 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $2,878 | 91 | $0 (2024) |
| Amgen Inc. | $1,779 | 80 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,738 | 87 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,063 | 42 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,017 | 47 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $955.67 | 50 | $0 (2024) |
| PFIZER INC. | $902.25 | 44 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $667.39 | 22 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $596.33 | 27 | $0 (2022) |
| AbbVie Inc. | $502.25 | 27 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $680.39 | 30 | Novartis Pharmaceuticals Corporation ($158.27) |
| 2023 | $1,410 | 43 | Janssen Pharmaceuticals, Inc ($411.16) |
| 2022 | $1,679 | 75 | Janssen Pharmaceuticals, Inc ($378.03) |
| 2021 | $1,790 | 88 | Janssen Pharmaceuticals, Inc ($407.89) |
| 2020 | $1,210 | 57 | Janssen Pharmaceuticals, Inc ($251.22) |
| 2019 | $2,495 | 114 | Janssen Pharmaceuticals, Inc ($528.84) |
| 2018 | $3,088 | 144 | Amgen Inc. ($481.39) |
| 2017 | $3,294 | 156 | Janssen Pharmaceuticals, Inc ($480.14) |
All Payment Transactions
707 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: Bone Health | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $28.19 | General |
| Category: Cardiovascular | ||||||
| 11/11/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/04/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: RESPIRATORY | ||||||
| 10/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: DIABETES | ||||||
| 10/25/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Bone Health | ||||||
| 10/14/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: RESPIRATORY | ||||||
| 10/07/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: DIABETES | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $30.83 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/13/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/05/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/05/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $13.81 | General |
| Category: Coronary | ||||||
| 06/04/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Cardiology | ||||||
| 06/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: RESPIRATORY | ||||||
| 05/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.53 | General |
| Category: DIABETES | ||||||
| 05/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $32.30 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/15/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/08/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Cardiology | ||||||
| 04/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $32.30 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,930 | 3,606 | $1.6M | $213,635 |
| 2022 | 21 | 2,005 | 4,195 | $1.6M | $237,186 |
| 2021 | 16 | 2,187 | 4,752 | $2.1M | $299,454 |
| 2020 | 19 | 2,079 | 4,310 | $2.0M | $256,408 |
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 259 | 487 | $267,850 | $54,850 | 20.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 287 | 586 | $219,750 | $45,104 | 20.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 227 | 236 | $456,660 | $40,759 | 8.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 411 | 1,143 | $165,735 | $14,419 | 8.7% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2023 | 36 | 36 | $89,028 | $9,204 | 10.3% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 46 | 50 | $87,300 | $9,065 | 10.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 39 | 39 | $68,484 | $7,246 | 10.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $48,853 | $7,229 | 14.8% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 29 | 29 | $59,682 | $6,543 | 11.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 43 | $32,035 | $6,447 | 20.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 324 | 709 | $14,692 | $5,956 | 40.5% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 18 | 25 | $23,500 | $2,351 | 10.0% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 33 | 34 | $40,460 | $2,048 | 5.1% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 52 | 56 | $9,184 | $1,304 | 14.2% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 51 | 52 | $5,564 | $592.28 | 10.6% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 16 | 16 | $2,384 | $339.20 | 14.2% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 16 | 16 | $1,712 | $179.20 | 10.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 349 | 836 | $313,500 | $67,638 | 21.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 265 | 512 | $281,600 | $59,927 | 21.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 179 | 188 | $363,780 | $33,093 | 9.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 418 | 1,418 | $205,610 | $18,872 | 9.2% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2022 | 44 | 48 | $83,808 | $8,984 | 10.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 43 | 49 | $36,505 | $8,541 | 23.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 37 | 37 | $64,972 | $6,943 | 10.7% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2022 | 25 | 25 | $61,825 | $6,773 | 11.0% |
About Dr. Leonid Chernov, M.D
Dr. Leonid Chernov, M.D is a Cardiovascular Disease healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1902801145.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leonid Chernov, M.D has received a total of $15,647 in payments from pharmaceutical and medical device companies, with $680.39 received in 2024. These payments were reported across 707 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($15,577).
As a Medicare-enrolled provider, Chernov has provided services to 8,201 Medicare beneficiaries, totaling 16,863 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Practice Information
- Specialty Cardiovascular Disease
- Location Brooklyn, NY
- Active Since 06/15/2005
- Last Updated 03/08/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1902801145
Products in Payments
- XARELTO (Drug) $2,584
- ENTRESTO (Drug) $1,113
- ELIQUIS (Drug) $1,067
- Repatha (Biological) $1,049
- JARDIANCE (Drug) $856.02
- LEQVIO (Drug) $625.21
- VERQUVO (Drug) $609.33
- Vascepa (Drug) $480.92
- FARXIGA (Drug) $442.84
- PRALUENT (Drug) $433.14
- BRILINTA (Drug) $384.19
- JANUVIA (Drug) $354.36
- Veltassa (Drug) $350.76
- PRALUENT ALIROCUMAB INJECTION (Biological) $340.68
- Corlanor (Drug) $334.67
- INVOKANA (Drug) $306.78
- Kerendia (Drug) $296.35
- PRADAXA (Drug) $294.04
- PRALUENT (Biological) $255.65
- CHANTIX (Drug) $231.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Brooklyn
Dr. Felix Yang, M.d, M.D
Cardiovascular Disease — Payments: $599,451
Ozgen Dogan, Md, MD
Cardiovascular Disease — Payments: $367,116
Dr. Adam Budzikowski, M.d., Ph.d, M.D., PH.D
Cardiovascular Disease — Payments: $346,063
Dr. Peter Rouvelas, M.d, M.D
Cardiovascular Disease — Payments: $339,378
Dr. Ronald Wharton, M.d, M.D
Cardiovascular Disease — Payments: $298,083
Dr. Sorin Brener, Md, MD
Cardiovascular Disease — Payments: $225,799